A recent study presented by Ming Shi, MD, PhD and colleagues at ESMO Virtual Congress 2020 found that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) yield more effective results in patients with unresectable hepatocellular carcinoma (HCC) compared with transarterial chemoembolization (TACE). In an interview with i3 Health, Dr. Shi shares insights about the significance of these results, as well as the future of treatment for HCC, and advice ...

A study presented at ESMO Virtual Congress 2020 revealed that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) yields more effective results in patients with unresectable hepatocellular carcinoma (HCC) compared with transarterial chemoembolization (TACE). For this randomized, multi-center, open-label trial (NCT02973685), results of which are published in Annals of Oncology, 315 patients aged 18 years or older with a primary unresectable HCC tu...

The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who have not previously received systemic therapy. The approval was based on IMbrave150 (NCT03434379), a phase 3 trial that enrolled 501 patients with unresectable HCC. Patients were randomized in a 2:1 ratio to receive atezolizumab 1,200 mg administered intravenously followed by be...

​The FDA has granted accelerated approval to the combination of nivolumab (Opdivo®, Bristol-Myers Squibb) and ipilimumab (Yervoy®, Bristol-Myers Squibb) for the treatment of patients with hepatocellular carcinoma following treatment with sorafenib. Safety and efficacy were evaluated in Cohort 4 of the phase 1/2 CHECKMATE-040 trial (NCT01658878), in which patients previously treated with sorafenib were randomized to receive either nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every three weeks for fo...

In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepatocellular carcinoma (HCC). However, the assessment of baseline liver function as a prognostic factor for patients with unresectable HCC receiving lenvatinib had not yet been investigated. In a post hoc analysis of the trial, a team of researchers led by Arndt Vogel, MD, Professor of Gastrointestinal Oncology at Hannover Medica...